- Company
- Shingrix lead mkt again…shakes shingles vaccine mkt
- by Chon, Seung-Hyun Nov 23, 2023 05:37am
- The annual KRW 40 billion shingles vaccine market has shown rapid changes. GlaxoSmithKline's (GSK) new shingles vaccine 'Shingrix' took an unrivaled lead in the Korean market. Shingrix’s market share exceeded 50% this quarter powered by its strong preventive effect despite its high price. According to the market research institution IQVIA on
- Company
- SK Bioscience & Hilleman Laboratories develop Ebola vaccine
- by Kim, Jin-Gu Nov 23, 2023 05:37am
- SK Bioscience announced on the 22nd that it signed a memorandum of understanding (MOU) with Hilleman Laboratories, an international non-profit research institute, for the joint development of a second-generation Zaire Ebola virus vaccine. Hilleman Laboratories was established in 2009 as an equal joint venture between MSD and Wellcome Tr
- Company
- Leukemia drug Xospata’s reimb limit may be resolved
- by Eo, Yun-Ho Nov 23, 2023 05:37am
- Astellas Korea is working to resolve the issue of the reimbursed number of cycles approved for its acute myeloid leukemia treatment ‘Xospata.’ Dailpharm’s coverage showed that the agenda on expanding reimbursement standards for Astellas Korea’s Xospata, a drug for patients with relapsed or refractory acute myeloid leukemia (AML) with
- Company
- Reimb of COVID-19 drugs necessary with eased crisis level
- by Eo, Yun-Ho Nov 22, 2023 05:30am
- Whether COVID-19 treatments will be able to be listed for reimbursement before Korea's COVID-19 containment measures are lifted remains under attention. Two COVID-19 treatments, Gilead Science Korea’s ‘Veklury (remdesivir)’ and Pfizer Korea’s ‘Paxlovid (nirmatrelvir+ritonavir),’ are currently under review by the Health Insurance Rev
- Company
- Mitsubishi’s Lou Gehrig's disease drug Radicut's sale soars
- by Nho, Byung Chul Nov 21, 2023 05:48am
- The latecomer injection formulations are taking over the Lou Gehrig's disease treatment market that had been occupied by injectables in the past. According to the industry’s pharmaceutical distribution performance data, Mitsubishi Tanabe Pharma Korea's Radicut Inj (edaravone) has occupied 39% of the market share in the related treatme
- Company
- IL inhibitor reimb as 1st-line Tx for ankylosing spondylitis
- by Eo, Yun-Ho Nov 21, 2023 05:48am
- Interleukin inhibitors may soon be available as first-line treatment for ankylosing spondylitis in Korea. On the 20th, the Ministry of Health and Welfare announced an amendment notice that contains a plan to expand insurance reimbursement for the 2 IL-17A inhibitors approved in Korea - Novartis Korea's 'Cosentyx (secukinumab)' and Lilly K
- Company
- Yuhan Leclaza clinical phase 3 cost exceeds 100 billion
- by Chon, Seung-Hyun Nov 20, 2023 05:50am
- The development cost invested by Yuhan's new anti-cancer drug Leclaza in the Phase 3 clinical trial has exceeded 100 billion won. Three years after the start of the clinical trial, the cost of development is also increasing. Yuhan was approved as a primary treatment based on the efficacy and safety of Leclaza confirmed in the clinical trial,
- Company
- ‘1+3 will also impact Korea’s patent linkage system'
- by Kim, Jin-Gu Nov 20, 2023 05:50am
- The so-called ‘1+3 restriction on bioequivalence testing’ system is expected to impact the Drug Approval-Patent Linkage System as well. If applied, the 1+3 system is expected to eradicate the practice of multiple generic companies jointly filing patent challenges and improve the practicality of the first generic exclusivity right (fi
- Company
- 160 billion won Daewoong·Takeda Luphere·Leuplin
- by Nho, Byung Chul Nov 17, 2023 06:00am
- Daewoong Pharmaceutical's Luphere and Takeda Pharmaceutical Leuplin are leading the market in the field of prostate cancer treatment. According to the drug distribution performance data, Luphere and Leuplin ranked 1st and 2nd based on single product sales in the first half of this year, with a performance of 15.4 billion won and 13.9 billio
- Company
- New drug Camzyos can be prescribed at hospitals
- by Eo, Yun-Ho Nov 17, 2023 06:00am
- The new drug Camzyos for obstructive hypersatic myocardial infarction is entering the general hospital prescription. According to the related industry, Camzyos of BMS Pharmaceutical Korea has passed the Drug Committee (DC) of medical institutions such as SMC and Sinchon Severance Hospital. Camzyos is the first and only treatment that select
